Request Demo
Recent blog posts
Latest Hotspot
8 min read
Cold agglutinin disease Indication Strategy Report 2026: C1s, Trials and Deals
23 July 2026
2026 Cold agglutinin disease strategy: epidemiology, C1s biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Evans syndrome Indication Strategy Report 2026: FcRn, Trials and Deals
23 July 2026
2026 Evans syndrome strategy: epidemiology, FcRn biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
POEMS syndrome Indication Strategy Report 2026: VEGF, Trials and Deals
23 July 2026
2026 POEMS syndrome strategy: epidemiology, VEGF biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Castleman disease Indication Strategy Report 2026: IL-6, Trials and Deals
23 July 2026
2026 Castleman disease strategy: epidemiology, IL-6 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Rosai-Dorfman disease Indication Strategy Report 2026: MAP2K1, Trials and Deals
23 July 2026
2026 Rosai-Dorfman disease strategy: epidemiology, MAP2K1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Erdheim-Chester disease Indication Strategy Report 2026: BRAF, Trials and Deals
23 July 2026
2026 Erdheim-Chester disease strategy: epidemiology, BRAF biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
MDS/MPN with neutrophilia Indication Strategy Report 2026: JAK2, Trials and Deals
23 July 2026
2026 MDS/MPN with neutrophilia strategy: epidemiology, JAK2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Langerhans cell histiocytosis Indication Strategy Report 2026: BRAF, Trials and Deals
23 July 2026
2026 Langerhans cell histiocytosis strategy: epidemiology, BRAF biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Juvenile myelomonocytic leukemia Indication Strategy Report 2026: RAS, Trials and Deals
23 July 2026
2026 Juvenile myelomonocytic leukemia strategy: epidemiology, RAS biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Chronic myelomonocytic leukemia Indication Strategy Report 2026: RAS, Trials and Deals
23 July 2026
2026 Chronic myelomonocytic leukemia strategy: epidemiology, RAS biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
B-cell acute lymphoblastic leukemia Indication Strategy Report 2026: CD19, Trials and Deals
23 July 2026
2026 B-cell acute lymphoblastic leukemia strategy: epidemiology, CD19 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
T-cell acute lymphoblastic leukemia Indication Strategy Report 2026: NOTCH1, Trials and Deals
23 July 2026
2026 T-cell acute lymphoblastic leukemia strategy: epidemiology, NOTCH1 biology, clinical competition, recent deals, unmet need and market attractiveness.